BioSpace News Archive

“The robustness and consistency of the CONDUCT results support our strategy to move cobitolimod forward in development and our phase III preparations are continuing according to plan,” says Peter Zerhouni, CEO of InDex Pharmaceuticals.

In 2019, with the continuous advancement of “three medical integration”, Chengdu Medical City’s three medical innovation center, as “Western China Biomedical Innovation Center”, submitted a satisfactory answer sheet

Stock market gains and dealmaking activity in Q4 clinched the biopharma sector’s strong performance in 2019 – a stark reversal of the declines seen in the final months of 2018.

Galderma today announced that The New England Journal of Medicine (NEJM) has published full results from the Phase 2 study of its investigational therapy nemolizumab in adult patients suffering from moderate-to-severe prurigo nodularis (PN).

111, Inc. has announced that it will leverage its knowhow and technology in the battle against the novel coronavirus public health crisis, through partnerships with some of China’s leading financial institutions to distribute medical services via apps to their extensive consumer bases.

On February 4th, Shanghai Public Health Clinical Center, one of the authoritative institutions in the field of infectious diseases in China and the core unit for the treatment of COVID-19 in Shanghai, published the article “AI Aids the Scientific Prevention and Control, Intelligent Evaluation System of Chest CT for COVID-19 Launched in Shanghai Public Health Clinical Center” on its official WeChat platform.

111, Inc. announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2019 ended December 31, 2019, before the open of U.S. markets on Thursday, March 12, 2020.

Foreign businesses in China are struggling with how to deal with the repercussions of the coronavirus outbreak.

Calidi Biotherapeutics, Inc. (“Calidi”), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, Heehyoung Lee, Managing Partner at LumeBio, to its board of directors

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced it has entered into a strategic collaboration agreement with GSK to develop novel adoptive cell therapies targeting multiple cancer indications.